Caffeine Citrate

證據等級: L5

預測適應症: 0 個

Caffeine Citrate: Repurposing Candidacy Evaluation — Prediction Not Yet Generated

One-Sentence Summary

Caffeine citrate is a methylxanthine formulation established for treating apnea of prematurity in neonates, acting as an adenosine receptor antagonist to stimulate the central respiratory system. The TxGNN model has not yet generated a repurposing prediction for this compound — the current Evidence Pack reflects an early-stage data collection run with critical gaps remaining. A Hold decision is recommended until the core data gaps are resolved and predictions are produced.

Quick Overview

Item	Content
Original Indication	Apnea of prematurity (neonatal); not registered in Taiwan
Predicted New Indication	Not yet generated
TxGNN Prediction Score	Not available
Evidence Level	L5 — No predictions generated; insufficient data for assessment
Taiwan Market Status	✗ Not marketed (0 authorizations)
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

This section cannot be completed in the current Evidence Pack cycle, as no TxGNN repurposing prediction has been generated for caffeine citrate. Without a candidate target indication, mechanistic plausibility cannot be assessed.

From general pharmacological knowledge: caffeine citrate is a water-soluble salt formulation of caffeine, a non-selective adenosine receptor antagonist (A₁ and A₂A subtypes). It stimulates the medullary respiratory centre, increases chemoreceptor sensitivity to CO₂, and reduces apneic episodes in premature infants. Its methylxanthine mechanism is shared with theophylline and could theoretically be relevant to other adenosine-pathway-mediated conditions — but this remains speculative without a TxGNN prediction to anchor the analysis.

Detailed MOA data was flagged as a High-severity data gap (DG002). The DrugBank query returned 1 result (see Query Log, ID 3), but the MOA field in the Evidence Pack remains unpopulated — this extraction step should be reviewed.

Clinical Trial Evidence

Currently no related clinical trials are registered for a repurposing indication — no TxGNN target indication has been generated, so no evidence search has been scoped.

Literature Evidence

Currently no related literature is available — evidence collection is blocked pending TxGNN prediction output.

Taiwan Market Information

Caffeine citrate is not currently registered or marketed in Taiwan. The TFDA query (Query Log, ID 1) returned 0 records. No authorization table is available.

Note: The TFDA package insert query (Query Log, ID 4) returned 1 result with result_status: success, yet safety warnings and contraindications in the Evidence Pack remain marked as [Data Gap]. The extracted content from this package insert should be reviewed and populated before the next evaluation cycle.

Safety Considerations

Please refer to the package insert for safety information.

The TFDA package insert was successfully retrieved (Query Log, ID 4), but warning and contraindication data was not extracted into this Evidence Pack. The DDI query returned no results (not found). Both issues require remediation before safety assessment can proceed.

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN repurposing predictions have been generated for caffeine citrate, and two critical data gaps — MOA and safety warnings — remain unfilled despite successful upstream queries, preventing any meaningful evaluation from proceeding.

To proceed, the following is needed:

Re-run TxGNN prediction pipeline for caffeine citrate to generate a candidate target indication (currently predicted_indications: [])
Extract MOA from DrugBank — query ID 3 returned 1 result but the original_moa field is [Data Gap]; review the DrugBank extraction step
Extract safety data from TFDA package insert — query ID 4 returned 1 result with result_status: success; key warnings and contraindications were not populated into the Evidence Pack
Confirm DDI scope — after a target indication is established, re-run the DDI query with condition-specific drug combinations
Assess Taiwan registration pathway — caffeine citrate has 0 TFDA licenses; if a repurposing indication is identified, a registration strategy will need to be developed from scratch
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.